Drugs Controller General of India (DCGI) had on May 1 accorded emergency approval for use of 2DG on COVID-19 patients. Drugmaker Laurus Labs has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market 2-Deoxy-D-Glucose (2DG), an oral drug indicated as an adjunct therapy for hospitalised COVID-19 patients. The Drugs Controller General of India (DCGI) had on May 1 accorded emergency approval for use of 2DG on COVID-19 patients. Laurus Labs is among a clutch of companies that have been issued licence to manufacture and market 2-DG, sources said. Last week, Shilpa Medicare had also announced receipt of an in-principle approval from DRDO for manufacture and sale of 2DG.

Source: The Hindu July 02, 2021 10:30 UTC